低水平MRD对成人急性淋巴细胞白血病的预后价值:低通量和高通量方法的检测
在GMALL 07/2003研究中,1019份首次巩固后骨髓样本按实时定量聚合酶链反应检测的克隆性免疫基因重排MRD结果分组:完全分子学缓解、分子学失败及分子学不可评估(MolNE)。MolNE组预后居中,其中NGS检测MRD阴性者预后显著优于阳性者。
要点
- 完全分子学缓解组5年OS为85%±2%,分子学失败组为40%±3%,MolNE组为66%±4%。
- MolNE组中NGS-MRD阴性者5年OS为88%±5%,NGS-MRD阳性者为37%±8%。
- MolNE不仅是临界值问题,还构成中危组,NGS可进一步改善其危险度分组。
核心结论
- MolNE MRD结果不仅是相关性存疑的临界值,还构成一个中危组,其分组可通过NGS进一步改善。
研究设计与样本
- GMALL 07/2003研究纳入1019份首次巩固后连续骨髓样本,采用实时定量聚合酶链反应检测克隆性免疫基因重排MRD,判别界值为1×10-4。
主要发现
- 完全分子学缓解组(n=603)5年OS为85%±2%,5年DFS为73%±2%(n=599)。
- 分子学失败组(n=238)5年OS为40%±3%,5年DFS为29%±3%(n=208)。
- MolNE组5年OS为66%±4%,5年DFS为52%±4%(n=178)。
- MolNE样本经NGS再分析,NGS-MRD不可测组(n=44)5年OS为88%±5%,5年DFS为70%±7%。
- NGS-MRD阳性组(n=42)5年OS为37%±8%,5年DFS为33%±8%。
关键数值与推荐
- MRD水平≥1×10-4定义为分子学失败。
- MRD阴性且检测灵敏度至少1×10-4定义为完全分子学缓解。
- 不符合上述类别的MRD结果称为分子学不可评估(MolNE)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Persistence of minimal residual disease (MRD) after induction/consolidation therapy in acute lymphoblastic leukemia is the leading cause of relapse. The GMALL 07/2003 study used MRD detection by real-time quantitative polymerase chain reaction of clonal immune gene rearrangements with 1 × 10-4 as discriminating cutoff: levels ≥1 × 10-4 define molecular failure and MRD-negativity with an assay sensitivity of at least 1 × 10-4 defining complete molecular response. The clinical relevance of MRD results not fitting into these categories is unclear and termed "molecular not evaluable" (MolNE) toward MRD-based treatment decisions. Within the GMALL 07/03 study, 1019 consecutive bone marrow samples after first consolidation were evaluated for MRD. Patients with complete molecular response had significantly better outcome (5-year overall survival [OS] = 85% ± 2%, n = 603; 5-year disease-free survival [DFS] = 73% ± 2%, n = 599) compared with patients with molecular failure (5-year OS = 40% ± 3%, n = 238; 5-year DFS = 29% ± 3%, n = 208), with patients with MolNE in between (5-year OS = 66% ± 4%; 5-year DFS = 52% ± 4%, n = 178). Of MolNE samples reanalyzed using next-generation sequencing (NGS), patients with undetectable NGS-MRD (n = 44; 5-year OS = 88% ± 5%, 5-year DFS = 70% ± 7%) had significantly better outcome than those with positive NGS-MRD (n = 42; 5-year OS = 37% ± 8%; 5-year DFS = 33% ± 8%). MolNE MRD results not just are borderline values with questionable relevance but also form an intermediate-risk group, assignment of which can be further improved by NGS.
引用
- Kotrová M, Koopmann J, Trautmann H, et al. Prognostic value of low-level MRD in adult acute lymphoblastic leukemia detected by low- and high-throughput methods. Blood Adv. 2022. PMID: 35026836. doi:10.1182/bloodadvances.2021006727
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。